clinical trial · NCT02099058
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie·phase1·active not recruiting·n = 237
Advanced Solid Tumors CancerOsimertinibNivolumabTelisotuzumab vedotinTelisotuzumab vedotinErlotinib
brief summary
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
started
Jan 15, 2014
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
Aug 14, 2025
official title
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol